Exegi Pharma LLC

ROCKVILLE, Md., Dec. 8, 2023 /PRNewswire/ -- ExeGi Pharma, a pioneering biopharmaceutical company dedicated to the development and commercialization of innovative live biotherapeutics, has announced the first patient enrollment in its landmark PROF Trial. The trial will study the potential of EXE-346, a novel live biotherapeutic, as treatment for excessive stool frequency in patients with an ileal pouch-anal anastomosis. Live biotherapeutics are similar to probiotics in that they contain live beneficial bacteria, however live biotherapeutics as therapeutic drug products require FDA approval. Ileal pouch-anal anastomosis (IPAA) is a surgical procedure often employed for patients with ulcerative colitis which results in a significantly altered gastrointestinal tract. A subset of these patients experience chronic excessive stool frequency, which severely impacts their quality of life. EXE-346 aims to offer hope and a potential solution to this issue. Dr. Hans Herfarth, the principal investigator for the PROF Trial and Director of the University of North Carolina Multidisciplinary IBD Center commented, "We are optimistic about the potential of EXE-346. This trial represents a significant step forward in our commitment to improving outcomes and advancing the standard of care for patients suffering from complications associated with ileal pouch-anal anastomosis." The PROF Trial is anticipated to provide valuable insights into the therapeutic application of EXE-346 in IPAA patients with debilitating stool frequency challenges. "We are excited to embark on this pivotal trial, and the enrollment of our first patient is a monumental milestone," said Marc Tewey, CEO of ExeGi Pharma. "We remain deeply committed to developing groundbreaking solutions and hope that EXE-346 will pave the way for a new era in the management of ileal pouch disorders." The PROF Trial will continue patient recruitment across multiple sites, aiming for robust and comprehensive results that will guide future applications of EXE-346. For more information on the PROF Trial, please refer to the clinicaltrials.gov posting (NCT05938465) or visit . About ExeGi Pharma ExeGi Pharma LLC is a biotechnology company focused on the development and commercialization of live biotherapeutic and probiotic medicines. ExeGi's team leverages scientific expertise in the field of microbiome science to deliver novel, clinically supported live biotherapeutic and probiotic products for a variety of unmet health and medical needs. ExeGi is headquartered in Rockville, Md. SOURCE ExeGi Pharma

First in class product aims to provide new therapeutic option for a common condition in cats ROCKVILLE, Md., Dec. 6, 2023 /PRNewswire/ -- ExeGi Pharma, leaders in therapeutic probiotic solutions, today unveiled Visbiome Vet Constipation Care, a revolutionary probiotic formulation designed to combat occasional constipation in cats. Continue Reading First-in-class probiotic for cat constipation aims to help pet parents with common feline condition This innovative product is the culmination of extensive research and development, combining unique probiotic strains specifically chosen to support feline gastrointestinal health. It's formulated to offer a safe and effective solution for occasional cat constipation, focusing on promoting regular bowel movements and nurturing a balanced microbiome, contributing to the overall well-being of cats. Speaking about the introduction of Visbiome Vet Constipation Care, Donna Raditic, DVM and Board-Certified Veterinary Nutritionist, stated, "The launch of Visbiome Vet Constipation Care is an important advancement in feline health solutions. Constipation in domestic cats is a common issue which seriously impacts the quality of life for many cats and their pet parents. We have significantly less research for our feline patients, so I am excited to use a scientifically backed nutritional solution like Visbiome Vet Constipation Care. It gives us a new tool for managing a complicated condition with limited therapeutic options." ExeGi Pharma is committed to pioneering the probiotic sector, developing cutting-edge products that are thoroughly researched and clinically tested to ensure unparalleled quality and efficacy. With Visbiome Vet Constipation Care, the company reiterates its commitment to elevating animal health through innovative and impactful probiotic solutions. About ExeGi Pharma ExeGi Pharma LLC is a biotechnology company focused on the development and commercialization of live biotherapeutic and probiotic medicines. ExeGi's team leverages scientific expertise in the field of microbiome science to deliver novel, clinically supported live biotherapeutic and probiotic products for a variety of unmet health and medical needs. ExeGi is headquartered in Rockville, Md. About Visbiome Vet Constipation Care Visbiome Vet Constipation Care contains SLAB51®, a high-potency, eight-strain probiotic blend. The SLAB51 formulation has been the subject of numerous clinical studies in domestic animals, including cat constipation. Additional studies are ongoing in a number of applications. SOURCE ExeGi Pharma LLC

ROCKVILLE, Md., Nov. 9, 2023 /PRNewswire/ -- ExeGi Pharma LLC, a leader in digestive health solutions, is proud to announce that its flagship product, Visbiome GI Care Probiotic Capsules, has achieved the prestigious Clean Label Project ® Certification and Clean Label Project Pesticide Free Certification. Continue Reading The Clean Label Project is a nonprofit organization committed to the transparency in product labeling The Clean Label Project is a national nonprofit consumer advocacy and standards development organization focused on health and transparency in consumer product labeling. Through its rigorous testing and certification program, the Clean Label Project ensures that products meet the highest standards for ingredient purity and quality. "Our customers trust Visbiome to support their digestive health with the highest-quality probiotics subjected to extensive clinical testing," said Marc Tewey, CEO of ExeGi Pharma. "Securing the Clean Label Project Certification is a testament to our unwavering commitment to provide products that not only are effective but also adhere to the highest ingredient standards." Visbiome GI Care High Potency Capsules underwent the Clean Label Project's rigorous testing process, which screens for over 200 impurities, including heavy metals, pesticides, plasticizers, and glyphosate. The Clean Label Project's distinctive seal will now be displayed on all Visbiome GI Care High Potency Capsules. This packaging assures consumers that the product meets strict criteria for purity. "We are delighted to recognize Visbiome GI Care High Potency Capsules for their exceptional commitment to purity and transparency," said Jaclyn Bowen, Executive Director of the Clean Label Project. "Their dedication is evident in their product and aligns with our mission to bring truth and transparency to the forefront of labeling." Visbiome GI Care High Potency Capsules are available for purchase online and from selected retailers nationwide. For more information about Visbiome® and the Clean Label Project, please visit and cleanlabelproject.org. About ExeGi Pharma ExeGi Pharma LLC is a biotechnology company focused on developing and commercializing live biotherapeutic and probiotic medicines. ExeGi's team leverages scientific expertise in the field of microbiome science to deliver novel, clinically supported live biotherapeutic and probiotic products for a variety of unmet health and medical needs. ExeGi Pharma is dedicated to creating environmentally friendly products that balance business needs with green initiatives. About the Clean Label Project® The Clean Label Project is a nonprofit organization committed to transparency in product labeling. Leveraging data and science to reveal the true contents of America's best-selling consumer products, the Clean Label Project awards its certification to brands that prioritize purity and environmental stewardship in their products. SOURCE ExeGi Pharma